Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAN-REST: Contrast-Associated Nephropathy Risk Evaluation in Acute Ischemic Stroke After Endovascular Thrombectomy

NCT06596603 is registered in ClinicalTrials.gov with Niguarda Hospital as lead sponsor.

NCT NCT06596603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06596603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAN-REST: Contrast-Associated Nephropathy Risk Evaluation in Acute Ischemic Stroke After Endovascular Thrombectomy
Lead sponsor
Niguarda Hospital
Phase
Observational
Overall status
Completed
Start date
March 1, 2023
Completion date
July 1, 2025
Enrollment
8,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

contrast-associated acute kidney injury